1. Academic Validation
  2. Discovery of Novel Small-Molecule Inhibitors Disrupting the MTDH-SND1 Protein-Protein Interaction

Discovery of Novel Small-Molecule Inhibitors Disrupting the MTDH-SND1 Protein-Protein Interaction

  • J Med Chem. 2025 Jan 23;68(2):1844-1862. doi: 10.1021/acs.jmedchem.4c02574.
Hao Shen 1 2 3 Jiayu Ding 1 2 3 Jiaying Ji 1 2 3 Lingrong Hu 1 2 3 Wenjian Min 1 2 3 Yi Hou 1 2 3 Dawei Wang 1 2 3 Yuanyuan Chen 1 2 3 Liping Wang 1 2 3 Yasheng Zhu 1 2 3 Xiao Wang 1 2 3 Peng Yang 1 2 3
Affiliations

Affiliations

  • 1 State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.
  • 2 Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
  • 3 Institute of Innovative Drug Discovery and Development, China Pharmaceutical University, Nanjing 211198, China.
Abstract

MTDH-SND1 protein-protein interaction (PPI) plays an important role in the initiation and development of tumors, and it is a target for the treatment of breast Cancer. In this study, we identified and synthesized a series of novel small-molecule inhibitors of MTDH-SND1 PPI. The representative compound C19 showed potent activity against MTDH-SND1 PPI with an IC50 of 487 ± 99 nM and tight binding to the SND1-purified protein with a Kd value of 279 ± 17 nM. Compound C19 significantly degraded SND1 and downregulated downstream at the protein level. Further biological evaluations suggested that compound C19 exhibited potent activity against the proliferation of breast Cancer MCF-7 cells with an IC50 value of 626 ± 27 nM, significantly inhibited invasion and migration, and induced cell Apoptosis. In addition, compound C19 exhibited promising tumor growth inhibition in the xenograft model. Our study provides a potential candidate targeting MTDH-SND1 PPI for the treatment of breast Cancer.

Figures
Products